Radiotherapy With Single-Agent Cisplatin or Combination Chemotherapy in Defined Poor-Prognostic Cervical Cancer
Status:
Unknown status
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
Concurrent radiotherapy with cisplatin-based chemotherapy has become the standard treatment
for patients with cervical cancer. However, in patients with advanced cervical cancer, half
of them treated with contemporary radiotherapy plus single agent cisplatin still suffered
from the local or distant relapse. How to improve the treatment outcome of these patients is
a very important issue and requires further clinical investigation.
The major aim of this project is to conduct a prospective, randomized phase III clinical
trial to examine if cervical cancer patients treated by radiotherapy with cisplatin and
gemcitabine have better survival rates than those treated by radiotherapy with cisplatin
alone.
Gemcitabine has been demonstrated to be a good radiosensitizer. In keeping with this, few
clinical trials in early phases showed promising results when using concurrent radiotherapy
with cisplatin and gemcitabine. According to these positive results, the investigators expect
this trial has the potential to improve the survival in patients with advanced cervical
cancer, reduce the medical costs due to tumor relapse, and then benefit the whole society.